Imagine a future where people with diabetes no longer have to inject themselves every day of their lives, and where children with cancer can be treated without painful needles piercing their skin.
Prometheon Pharma, LLC has technology that can create this reality, and we are bringing this advancement to everyone, regardless of location or socioeconomic condition.
The Company’s first product line under development, Topicon™DM, features insulin patches that provide continuous and consistent delivery of steady-state (basal) insulin—the therapeutic foundation for all insulin-treated persons with diabetes.
Our platform technology allows large therapeutic biomolecules to cross passively through the skin, a convenient and painless alternative to frequent injections and the first patches that are resistant to heat and allow perishable drugs to be activated only upon application.
Prometheon Pharma's Business Plan: https://app.box.com/s/79vbof3cfleecewpiwl4